Cipla eyes inorganic partnerships, acquisitions in US

Cipla MD and CEO Umang Vohra said that "derisking our top launches remains our top priority" as the company focuses on resolving regulatory issues at various manufacturing plants.

Published On 2024-02-05 10:00 GMT | Update On 2024-03-22 08:46 GMT

Mumbai: Drug major Cipla is eyeing acquisitions and inorganic partnerships in the US market while consolidating its presence across segments in the domestic market. The Mumbai-based company is also looking to improve the top line in Europe and margin expansion in South Africa.

"Product launches through delisting strategy and as well as inorganic partnerships and acquisitions will remain one of our key priorities for the US market," Cipla Global Chief Financial Officer Ashish Adukia said in an analyst call.

The drug maker would also focus on commercial execution of existing portfolios and resolution of USFDA observations, he added.

In the South African market, Cipla would build on its performance aided by growth in private and select tender business with greater emphasis on margin expansion, Adukia stated.

"In emerging markets and Europe, top priority is to improve top line while margins are maintained at sustainable levels," he said. As per the yearly trend, the fourth quarter will have an impact of weaker seasonality in India and North America, Adukia noted.

Elaborating on the domestic business, he stated that the key focus area would be to further strengthen growth levers for wellness portfolio among others.

Cipla MD and CEO Umang Vohra said that "derisking our top launches remains our top priority" as the company focuses on resolving regulatory issues at various manufacturing plants.

"Our focus continues on regulatory efforts in Goa and Indore. Earlier in this quarter, we have updated you of the warning letter we had received for the Indore facility, which was audited in February '23," he stated.

The company has duly responded to queries from USFDA and are now focusing on remediation, Vohra said.

For the October-December quarter, the drug firm reported total revenue from operations at Rs 6,604 crore as compared with Rs 5,810 crore in the year-ago period. Its consolidated net profit rose by 32 per cent to Rs 1,056 crore for the December quarter as against Rs 801 crore in the year-ago period.

Original news source: https://www.ptinews.com/story/business/cipla-eyes-acquisitions-inorganic-partnerships-in-us-market/1265027

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Cipla eyes inorganic partnerships, acquisitions in US

Cipla MD and CEO Umang Vohra said that "derisking our top launches remains our top priority" as the company focuses on resolving regulatory issues at various manufacturing plants.

Similar News

Natco Pharma to buy significant stakes in South African Drugmaker Adcock Ingram

Tamil Nadu cancels licence of Sresan Pharma, orders shutdown

ED arrests Himachal Assistant Drug Controller in corruption case

Indore pharma unit under fire as inspection flags 216 lapses

Zydus, Dr Reddy's recall products in US over manufacturing issues

Biocon gets 1 USFDA observation for Cranbury site

Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion

Lupin gets 1 USFDA observation for Somerset facility